Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1873
No trial phase data available
No trial data available
No trial data available
No approval data available
- SK Capital Partners has agreed to sell Noramco's API-related assets to Swiss CDMO Siegfried Holding AG while retaining ownership of Halo Pharmaceuticals as a standalone entity. - Halo Pharma will focus exclusively on drug product contract development and manufacturing services across its facilities in Whippany, New Jersey and Mirabel, Quebec. - The company plans to launch sterile CDMO capabilities in the second half of 2026 with a state-of-the-art Groninger UFVN FlexFill filling line and Skan isolator system. - L. Lee Karras will assume the role of CEO for the independent Halo Pharma following the transaction's completion.
- The FDA has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, in addition to its existing diabetic macular edema indication. - ANI Pharmaceuticals plans to begin marketing ILUVIEN under the combined label later this year, enhancing treatment options for patients with these serious ocular conditions. - The company has extended its supply agreement with Siegfried Holding AG through 2029, including upgrades to manufacturing equipment and significant capacity expansion to ensure product availability.
